Janney Montgomery Scott LLC Boosts Stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

Janney Montgomery Scott LLC grew its position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 39.5% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 2,079,281 shares of the company's stock after purchasing an additional 588,295 shares during the quarter. Janney Montgomery Scott LLC owned approximately 0.18% of Teva Pharmaceutical Industries worth $31,959,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. Oarsman Capital Inc. bought a new position in shares of Teva Pharmaceutical Industries during the 4th quarter worth approximately $29,000. Marshall & Sterling Wealth Advisors Inc. acquired a new position in shares of Teva Pharmaceutical Industries during the 4th quarter valued at $44,000. Compagnie Lombard Odier SCmA acquired a new position in shares of Teva Pharmaceutical Industries during the 1st quarter valued at $54,000. IFP Advisors Inc boosted its stake in Teva Pharmaceutical Industries by 96.1% during the fourth quarter. IFP Advisors Inc now owns 3,999 shares of the company's stock worth $88,000 after acquiring an additional 1,960 shares in the last quarter. Finally, Quadrant Capital Group LLC grew its holdings in Teva Pharmaceutical Industries by 27.7% in the fourth quarter. Quadrant Capital Group LLC now owns 4,377 shares of the company's stock worth $96,000 after purchasing an additional 949 shares during the period. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

TEVA has been the topic of several research reports. The Goldman Sachs Group initiated coverage on shares of Teva Pharmaceutical Industries in a report on Friday, June 6th. They set a "buy" rating and a $24.00 price objective on the stock. Bank of America upped their price target on Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the stock a "buy" rating in a research note on Thursday, May 8th. JPMorgan Chase & Co. upgraded Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and increased their price target for the stock from $21.00 to $23.00 in a report on Monday, May 12th. Hsbc Global Res upgraded Teva Pharmaceutical Industries to a "strong-buy" rating in a report on Monday, April 28th. Finally, Wall Street Zen raised Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research report on Thursday, May 22nd. Nine research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $24.44.

Teva Pharmaceutical Industries Stock Up 1.1%

Shares of Teva Pharmaceutical Industries stock traded up $0.18 on Wednesday, hitting $17.07. The company had a trading volume of 11,691,727 shares, compared to its average volume of 10,223,787. Teva Pharmaceutical Industries Ltd. has a 1 year low of $12.47 and a 1 year high of $22.80. The company has a debt-to-equity ratio of 2.59, a quick ratio of 0.74 and a current ratio of 1.03. The stock has a 50 day moving average of $16.18 and a 200-day moving average of $17.42. The stock has a market capitalization of $19.58 billion, a price-to-earnings ratio of -14.84, a P/E/G ratio of 0.90 and a beta of 0.60.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $0.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.47 by $0.05. Teva Pharmaceutical Industries had a positive return on equity of 45.44% and a negative net margin of 7.74%. The business had revenue of $3.89 billion during the quarter, compared to the consensus estimate of $3.99 billion. During the same quarter in the prior year, the company posted $0.48 earnings per share. Teva Pharmaceutical Industries's revenue was up 1.9% compared to the same quarter last year. As a group, sell-side analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current year.

Insider Activity at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, EVP Matthew Shields sold 6,206 shares of the business's stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $17.02, for a total value of $105,626.12. Following the transaction, the executive vice president now directly owns 9,989 shares in the company, valued at $170,012.78. The trade was a 38.32% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.55% of the stock is currently owned by company insiders.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.